How Flu Vaccine Provide Immuinty Agains Flue
Adept Rev Vaccines. Author manuscript; bachelor in PMC 2013 Jun ane.
Published in final edited form every bit:
PMCID: PMC3514506
NIHMSID: NIHMS418423
Understanding the immune response to seasonal influenza vaccination in older adults: a systems biological science approach
Nathaniel D Lambert
oneMayo Clinic Vaccine Inquiry Group, Mayo Clinic, Guggenheim 611C, 200 1st Street SW, Rochester, MI 55905, The states
Inna G Ovsyannikova
1Mayo Dispensary Vaccine Research Grouping, Mayo Clinic, Guggenheim 611C, 200 1st Street SW, Rochester, MI 55905, Us
V Shane Pankratz
2Department of Health Sciences Enquiry, Mayo Clinic, Guggenheim 611C, 200 1st Street SW, Rochester, MI 55905, U.s.a.
Robert M Jacobson
iMayo Dispensary Vaccine Inquiry Grouping, Mayo Dispensary, Guggenheim 611C, 200 1st Street SW, Rochester, MI 55905, USA
threeDepartment of Pediatric and Boyish Medicine, Mayo Clinic, Guggenheim 611C, 200 1st Street SW, Rochester, MI 55905, USA
Gregory A Poland
oneMayo Clinic Vaccine Research Group, Mayo Clinic, Guggenheim 611C, 200 1st Street SW, Rochester, MI 55905, USA
Abstract
Almanac vaccination confronting seasonal influenza is recommended to decrease disease-related mortality and morbidity. However, one population that responds suboptimally to influenza vaccine is adults over the age of 65 years. The natural aging process is associated with a complex deterioration of multiple components of the host immune arrangement. Research into this phenomenon, known as immunosenescence, has shown that aging alters both the innate and adaptive branches of the allowed system. The intricate mechanisms involved in allowed response to influenza vaccine, and how these responses are altered with age, have led us to adopt a more encompassing systems biology approach to understand exactly why the response to vaccination diminishes with age. Here, the authors review what changes occur with immunosenescence, and some immunogenetic factors that influence response, and outline the systems biology arroyo to sympathise the immune response to seasonal influenza vaccination in older adults.
Keywords: bioinformatics, immunogenetics, immunosenescence, influenza, seasonal flu vaccine, systems biology, vaccinomics, vaccine-induced immunity
Flu vaccinology is rapidly changing. From the point of view of vaccine recommendations, we take moved from a 'i size fits all', chance-based approach to a population arroyo that at present calls for all Americans anile 6 months and older to be immunized annually. Withal, as far as which vaccine formulation to employ, we have moved to a more individualized, directed approach [i]. This is evident in the recent licensure and availability of both high-dose trivalent influenza vaccines (HD-TIVs) and intradermal trivalent flu vaccines, respectively, in the United states of america [201]. In Europe, an MF59-adjuvanted vaccine is available, and the pipeline of flu vaccine evolution continues to abound.
Inside this field is an area of special business organization: immunosenescence and the resulting decreased immunogenicity and efficacy of influenza vaccines in older persons. This concern results from the reality that the older private is more susceptible to morbid infection, may be unable to mount an effective vaccine-induced protective response, and is likely to have concomitant comorbidities that either contribute to the higher rates of morbidity and mortality if influenza infection results, and/or further impairs the evolution of an constructive immune response to vaccine. While these are issues of considerable research, to date, the understanding of immunosenescence remains limited. In turn, this impairs our power to devise vaccines or adjuvants that tin can overcome such barriers. For this reason, an expanded research agenda and approaches to sympathize immunosenescence and its relationship to vaccine-induced immunity is essential.
In this review, the authors summarize data on the epidemiology of influenza in older persons, the electric current agreement of immunosenescence, the role of immunosenescence in reduced vaccine immunogenicity and finally, discuss a systems biology and vaccinomics arroyo to unraveling the impact of immunosenescence on decreased vaccine immunogenicity and the application of such noesis to the development of improved influenza vaccines for older persons [ii].
Epidemiology of influenza in older adults
While older adults suffer the highest rates of hospitalization and bloodshed, they neither have the highest rates of infection nor stand for major contributors to local outbreaks. Local outbreaks begin suddenly and unaccountably, superlative over a 2–3-week period and then persist for ii–3 months. The timing and nature of these outbreaks remain unpredictable, unexplained and a target for scientific speculation [three–half-dozen]. In an outbreak, the first cases of influenza announced in schoolhouse-anile children and so spread to adults, including older adults, infants and younger children. Attack rates vary from x to 20% in the general population, reaching assail rates in the general population of more than 50% during a pandemic; assault rates tin can be extraordinarily high in institutional settings.
Despite having no higher attack rate than in younger adults, flu'south effects are more than significant in older adults. Barker'southward study focusing on the impact of influenza infection in the frail elderly showed a decline in functional status measurable 3–4 months after infection on at least one major function (e.g., bathing, dressing or mobility) for 25% of older patients residing in nursing homes as compared with 15.vii% of controls – randomly selected residents living in the same facility non contracting influenza or influenza-like illness during the same outbreak [vii].
Every bit mentioned before, older adults also have higher rates of hospitalization and mortality. Thompson et al. used the CDC's influenza-infection surveillance data and the National Hospital Discharge Survey data to estimate the annual influenza-related hospitalization rates in the USA [viii]. The results showed that hospitalization greatly increased with age in those aged 65 years and older; specifically, the rates increased with each 5-yr block of age from 65 to 69, to 85 years and older. Where pneumonia or influenza was listed equally the master diagnosis, the average hospitalization charge per unit was 36.eight per 100,000 person-years, but this increased in older persons from 37.9 for those 50–64 years onetime, to 71.one for those 65–69 years sometime, to 127.8 for those 70–74 years of age, to 302.2 for those 80–84 years old, and 628.6 for those aged 85 years and older. Furthermore, the length of infirmary stay also increased with age from a median of 3 days for those less than 5 years of age, to 4 days for those 5–49 years of historic period, to half-dozen days for those l–74 years of historic period, to 7 days for those 75 years and older.
Death rates from pneumonia and influenza in the United states of america have ranged from 5000 to 50,000 a year equally a effect of cardiovascular and respiratory pathology and depending upon the circulating influenza strain. While hospital rates in older adults approximate the hospital rates in infants and children younger than 2 years of age, the fatality charge per unit associated with the elderly is much higher. Thompson et al. establish in their study that mortality rates due to influenza have increased from the years 1976 to 1999, which they explained in part due to the aging of the United states population [9]. While the bloodshed rates from underlying pneumonia or influenza for those younger than l years of age ranged from 0.3 per 100,000 person-lives, the rates increased at 50 years of age and in a higher place [9]. The rates were ane.three per 100,000 person-lives for those 50–64 years of age and 22.one person-lives for those 65 years and older [ix]. The increased death rate establish in this written report matched findings of other investigations [ix,10]. Increasing the risk of mortality are the presence of high-take a chance medical weather condition; Nordin et al. found the lowest risk of mortality among those with no high-run a risk medical conditions who were 65–74 years of age, and the highest risk of bloodshed among those with loftier-risk medical conditions who were 75 years and older [10].
Using 2003 data, Molinari et al. estimate that the total financial burden of seasonal influenza infection in the USA amounts to $x.four billion a twelvemonth and that the older population comport 64% of the total economic burden [11]. Efforts to target the reduction of the illness burden in the older population therefore would have a substantial bear on on the expense of seasonal influenza [11].
Vaccine efficacy & induced immune response in older adults
Vaccine efficacy against influenza illness in older adults is hard to mensurate and reliable data are scarce. To appointment, in that location has been only one placebo-controlled trial of influenza vaccine efficacy against laboratory-confirmed illness in older adults [12]. The report estimated protection from influenza illness at approximately 50%. An alternative and widely accustomed approach is the measurement of influenza-specific antibiotic titers as a correlate of protection. Titers are traditionally measured using a hemagluttination inhibition (HAI) analysis, which quantifies the ability of hemagglutinin (HA)-specific antibodies to block N-acetylneuraminic acid-mediated viral agglutination of red claret cells [xiii,xiv]. Using the set guidelines of this assay, vaccine protection can be assessed based on patient seroconversion (fourfold increase in antibiotic titers postvaccination) and seroprotection (HAI antibody titers ≥1:forty postvaccination). Although some discrepancies exist in studies focusing on antibody response to influenza vaccine in older adults, a quantitative review concluded that HA-neutralizing antibodies are considerably lower in vaccinated older adults than in younger adults [fifteen]. There is also a correlation between health condition in older adults and HAI titers, with salubrious older adults having statistically significant college levels of HAI titers than those with chronic diseases [16].
A strain-specific robust humoral response to influenza is necessary to prevent master infection, but eventual viral clearance is dependent on the presence of CD8+ T cells directed toward conserved regions of the virus [17]. Influenza-specific CD8+ T cells produce antiviral mediators and directly kill infected cells [18]. Another approach used to measure cellular-mediated efficacy of flu vaccines against laboratory-confirmed disease is to quantify the ratio of IFN-γ:IL-ten and the cytolytic enzyme granzyme B from T cells postvaccination [nineteen]. Specifically, granzyme B production has been reported as a direct method of assessing vaccine failure and subsequent disease in older adults [20,21]. Furthermore, several studies accept demonstrated a defect in the product of IFN-γ and granzyme B in CD8+ T-cell subsets obtained from vaccinated older adults [22–24].
To overcome the macerated immune response observed in older adults, an 'increment the firepower' approach has been adopted. HA concentrations for each strain of 60 μg or more, as compared with 15 μg of HA in the standard trivalent inactivated vaccine (SD-TIV), result in increased immunogenicity for flu A strains and noninferiority for influenza B in older adults [25,26]. This led to the conception of an United states of america FDA-licensed high-dose vaccine for adults 65 years or older [202]. Each Hd-TIV contains 60 μg of HA antigen for each H1N1, H3N2 and B strain contained in the SD-TIV. The HD-TIV was more than immunogenic for both flu A virus strains in older adults than the SD-TIV in a Phase Three trial [27]. Nevertheless, both antibody and cell-mediated immune responses in older adults vaccinated with the Hard disk drive-TIV never reach the same levels observed in immature adults vaccinated with a standard-dose vaccination [28]. Although the antibody titers accomplished with the high-dose influenza vaccine in older adults may be effective against circulating influenza strains, the increasing emergence of deadlier strains demands the development of vaccines that focus on more than just increasing antigen dose. An crumbling immune system may not be able to mountain a sufficiently protective response to current or novel strains regardless of the corporeality of antigen present without the addition of adjuvants or newer methods of antigen commitment.
Immunosenescence
A key factor driving vaccine failure in older adults is immunosenescence. Immunosenescence is a broad term used to describe circuitous alterations in the allowed response attributed to aging. As the immune system ages, there is a significant increase in susceptibility to infection, autoimmunity and cancers, and a decrease in vaccine-induced amnesty [29]. At a cellular level, immunosenescence is a combination of diminished immune cell numbers and function, coupled with an inappropriate/unregulated inflammatory response that results in less than ideal amnesty. The following sections summarize published work that addresses the influence of immunosenescence on the innate and adaptive allowed systems and how these backdrop may diminish vaccination response in older adults.
Immunosenescence & the innate response
The innate branch of the immune arrangement affords the host power to respond rapidly and nonspecifically to an invading pathogen past host pattern recognition receptors (PRRs) [30]. Specifically, influenza virus has been shown to interact with innate signaling mediators, Toll-like receptors (TLRs; e.g., TLR7), Nod-like receptors (e.g., NLRP3, NOD2) and RIG-I-like receptors [31–34]. Along with initial pathogen clearance, innate immunity is also responsible for the genesis of the adaptive response by recruiting immune effector cells [35]. An age-related deficiency in innate immunity can negatively influence whatever subsequent adaptive response. As described below, there is mounting prove that the phenotypic responses of many components of innate immunity are influenced past immunosenescence.
Monocytes, dendritic cells, NK cells and other innate immunity cells express TLRs [36]. The interactions between conserved molecular patterns present on microbial pathogens and TLRs atomic number 82 to a MyD88 or TRIF-dependent induction of proinflammatory cytokines and the upregulation of type I interferons [37]. There is increasing evidence that a combination of inappropriate activation of TLRs and macerated office in response to many ligands is present in an anile population. Peripheral blood mononuclear cells from older adults produce decreased levels of IL-half-dozen and TNF-α and TLR1 surface expression levels are reduced after stimulation with a TLR1/two ligand [38]. In the context of viral infection, pro-inflammatory cytokine production and TLR3 expression levels are increased on West Nile virus-infected macrophages from older human donors, which may result in an inappropriate inflammatory response [39]. Plasmacytoid dendritic cells from aged donors secrete decreased amounts of both IFN-1 and IFN-Three afterwards stimulation with both the TLR7 ligand CpG and live influenza virus, which is due to damage in IRF-seven phosphorylation [twoscore]. These plasmacytoid dendritic cells also showroom diminished induction and priming of CD4/CD8 T-cell immunity. Panda et al. demonstrated a correlation betwixt defects in cytokine response from aged human dendritic cells stimulated with TLR ligands and macerated influenza vaccine-induced antibiotic production [41]. Taken together, impaired TLR response in immune cells from older adults directly affects both cellular and humoral immunity to influenza.
CD80 and CD86 are costimulatory molecules expressed on antigen-presenting cells and help activate T cells afterward interaction with CD28 [42,43]. Costimulatory molecule expression on TLR-activated monocytes can predict influenza vaccine allowed response in both young and older adults; in ane study, TLR-induced CD80 levels were approximately 68% less in older adults (p = 0.0002) compared with immature adults [44]. A decreased ability to interact with and activate effector T cells would ultimately result in both a deficient cellular and humoral response to vaccine.
NK cells are vital to the clearance of viral infection by the product of IFN-γ and lysis of infected cells [45]. Multiple studies have highlighted the importance of NK cells during influenza infection in both humans and mice [46–49]. NK cell activity in human subjects is augmented by influenza vaccination [fifty]. Interestingly, the overall numbers of NK cells are increased in healthy older adults [51]. Nonetheless, the function and number of NK cells decrease with diminished health condition, and NK activity correlates with health condition and HAI titers in vaccinated older adults [xvi,52]. Any perturbation in NK cell function would be detrimental to the development of a protective immune response to infection.
In dissimilarity to the many macerated responses associated with immunosenescence is the subclinical hyperinflammatory state known equally 'inflamm-aging' [53]. Immune cells isolated from older adults produce college concentrations of inflammatory cytokines, such as IL-1β, IL-half dozen and TNF-α afterward stimulation. Serum IL-6 levels increase with historic period in humans and are associated with disability and geriatric frailty [54–56]. Constant inflammation could get out a host susceptible to infection by not having the ability to recognize a true inflammatory response to a pathogen. This is true in a mouse model of systemic herpes viral infection, where an elevated land of inflammation increases susceptibility [57]. Vaccination failure and susceptibility to influenza illness may be a result of too much inflammation and non plenty regulation.
Immunosenescence & the adaptive response
Os marrow-derived T-prison cell progenitors undergo evolution and option in the thymus and sally every bit mature naive T cells [58]. Ane of the more than dramatic observations associated with aging is thymic involution, which results in a measurable decrease in circulating levels of new naive T cells [59]. Surprisingly, there is no modify in overall circulating T-cell numbers with age [60]. Research postulates that T-jail cell homeostasis and the production of new T cells is maintained through clonal expansion of peripheral, antigen-specific T cells [61].
An adverse effect of new T cells produced from existing T cells is a subtract in the diversity of T-cell receptors (TCRs) [62]. A robust immune response to flu infection is dependent on TCR diversity and there is evidence of a subtract in flu-specific CD8+ T-jail cell repertoire in older adults [22,63]. T-jail cell population diverseness is as well diminished in older adults after lifelong exposure to sure antigens and the accumulation of retention T cells [64].
A decline in T-prison cell multifariousness and massive expansion of memory T-cell clones has also been linked to persistent viral infections. For example, chronic infection with CMV in the older population results in extensive accumulation of exhaustive, high-analogousness, CMV-specific memory T cells [65]. CMV-specific CD8+ T cells also produce higher levels of IFN-γ, which could partly explicate age-associated 'inflamm-crumbling' [66]. The abundant numbers of CMV-specific retentivity T cells lone tin can alter homeostasis and decrease the corporeality of circulating naive T cells.
The expression of the costimulatory molecule CD28, which is needed for differentiation of naive T cells after initial antigen exposure, on CD8+ T cells decreases with age [67]. In that location is also a straight link between a decrease in CD28 expression (CD8+ CD28− T cells) and a poor allowed response to flu vaccine. In 1 study, a 10% proportional increment in CD8+ CD28− cells correlated with a 24% subtract in humoral response to flu [68]. The presence of other tardily effector T-cell subsets (CD8+ KLRG1howdy CD57hi) is also inversely correlated with influenza vaccine immunogenicity [69]. The identification of specific cellular subsets in older adults that successfully predict immune outcome could be a powerful tool in developing the next generation of vaccines.
A portion of decreased humoral response in older adults can also be attributed to a deficiency in extrinsic cellular signaling betwixt CD4+ T cells and B cells [70]. Senescent CD4+ T cells express lower levels of CD154 (CD40L) and this molecule is crucial for stimulation of B cells. Antibody response in older adults is likewise altered by a shift in B-cell homeostasis from naive to effector cells similar to that observed in T cells [71]. B-cell course switching, recombination and somatic hypermutation are as well defective in older populations [72]. This defect would result in an inability to produce high-affinity antibodies against influenza.
In summary, immunosenescence and its contribution to suboptimal vaccine response in older adults is a complex and multi-faceted process. The majority of research has focused on pinpointing atypical components of the immune organisation responsible for a diminished response. In reality, many fundamental systems contribute to immunosenescence. A successful model to predict and define vaccine result in older adults must therefore take into account not simply individual aspects of the aging immune system, but also other systems, such as epigenomic, genomic, proteomic and transcriptomic factors.
Immunogenetic factors associated with host responses to seasonal influenza vaccine
Relationships between genetic polymorphisms (and nongenetic factors) and immune response to influenza vaccine in the human population accept been reported [73–76]. With regard to human influenza infection, prove was found for a heritable predisposition to the development of astringent flu virus infection and death, strongly suggesting genetic associations with the immune response to influenza infection [77,78]. It is also idea that the predisposition to a fatal issue of influenza illness besides depends on environmental, nutritional, demographic and virologic factors [79]. The authors of these reports comment that "… it is important to identify those genes associated with the power to respond (to influenza) with protective immunity after natural or vaccine challenge" [77]. One specific gene responsible for the anti-inflammatory response to astringent influenza infection is the inducible rut shock protein gene, heme oxygenase-1 (HO-one) [80]. Recent studies have demonstrated the lungs of mice that were infected with highly pathogenic strains of flu virus exhibited increased levels of HO-1 gene expression and a decrease in the expression levels of antioxidants Gpx3 and Prdx5 [81]. Furthermore, dumb antibiotic product in response to influenza vaccination was observed in anile HO-ane-scarce mice [82]. Importantly, a recent study suggested that decreased flu vaccine response in humans is associated with polymorphisms in the HO-1 gene [82]. Besides, in a genome-broad clan study of 147 flu-vaccinated individuals, promoter SNP rs743811 and intronic SNP rs2160567 in the HO-one and constitutively expressed isoform HO-2 genes, respectively, were found to exist associated with decreased H1-specific HAI titers following influenza vaccine [82]. Thus, the HO-one and other gene polymorphisms should be investigated to better understand possible genetic determinants for influenza disease and vaccine effectiveness.
Host genetic polymorphisms probably play a pregnant role in immunity confronting influenza vaccine. In that location is limited immunogenetic data bachelor to explain pregnant interindividual variations observed in allowed response to flu vaccines. Population-based association studies revealed the importance of HLA and other immunity-related gene polymorphisms in influenza vaccine-induced humoral immunity [73,76]. HLA class I and form Two molecules present antigenic epitopes to CD8+ and CD4+ T cells, respectively, and initiate adaptive allowed responses. Influenza-derived peptide presentation by HLA class I and class II molecules induces T-cell populations with diverse specificities and functions [83,84]. Various HLA grade I (A*two, A*11, B*27 and B*35) and class II (DRB1*07, DRB1*13 and DQB1*06) alleles have been reported to correlate with the serologic response to influenza vaccination [73,76,85]. These differences in HLA class I and course II pathway presentations of immunodominant epitopes are probable the source for some proportion of the interindividual variation in influenza vaccine-induced immune responses.
Preliminary data from the candidate cistron studies demonstrate meaning correlations between flu H1-specific HAI antibiotic levels and unmarried nucleotide polymorphisms (SNPs) in cytokine (IFNG, IL6, IL12A, IL12B and IL18), and cytokine receptor (IFNAR2, TNFRSF1A, IL1R, IL2RG, IL4R, IL10RB and IL12RB) genes (range of p values 0.005–0.045) [76]. Associations were also discovered betwixt polymorphisms in genes regulating vitamin A receptor retinoic acrid receptor γ and innate immunity (TLR4) and variations in influenza H1-specific antibody levels [Poland GA, Ovsyannikova IG, Jacobson RM, Unpublished Data]. For instance, in the pilot studies, an increased frequency of the minor allele of the 5′UTR SNP (rs7398676; p = 0.08) in the retinoic acid receptor γ gene was associated with protective serum H1 antibody titers (median HAI titer of i:320) later influenza vaccine. Similarly, an intronic SNP (rs1927907; p = 0.one) in the TLR4 gene was marginally correlated with college H1 antibiotic levels (median HAI titer of i:320); however, a larger sample size is needed in guild to meliorate statistical power and conviction. These preliminary data provide bear witness that the immune-related gene polymorphism is associated with influenza H1-specific antibody titers later vaccination.
In addition to the findings associated with TLR4, it has been demonstrated that gene polymorphisms in TLR4 (that recognizes lipopolysaccharide) may influence innate immune responses to respiratory syncytia virus and influence the predisposition to severe respiratory syncytia virus disease [86,87]. Another study of the transcriptional targets of immune responses to influenza virus in homo peripheral blood mononuclear cells following influenza vaccination demonstrated a loftier expression of interferon-induced and -regulated genes, including IFN-γ-induced poly peptide precursor 10 (IP-ten) gene, suggesting their office in immune response to flu antigens [78]. In addition, the RIG-I gene is involved in the influenza virus-specific production of IFN-β. Also, influenza virus non-structural protein-1 has been demonstrated to collaborate with RIG-I and inhibit the RIG-I pathway, thereby inhibiting the generation of IFN-β [88]. By agreement genetic influences on the generation of amnesty due to vaccination, it is feasible to develop new vaccines confronting influenza [1,89–92]. By applying knowledge on the interactions of various pathways of primal gene families critical to developing protective allowed responses, it is viable to gain an agreement of the host response to influenza vaccine antigens.
Systems biology arroyo
Each of the aforementioned components is an important individual contributor to the power of an older developed, or indeed whatsoever individual, to mount an effective immune response following vaccination against influenza; evidence supporting their roles has been well established. While this understanding has come through extensive studies, these investigations accept primarily focused on relatively small components of the allowed system. In order to fully understand the way in which vaccines induce protection confronting foreign antigens, information technology is important to take a broader view of the components of the system that together give rise to immunity. In the study of biological processes, approaches are being developed that address this more expansive view and use more comprehensive modeling techniques that are integrated with existing biologic knowledge bases [93–96]. These approaches comprehensively integrate information gathered from a variety of often high-throughput, high-dimensional assays with human-collated models of biological part. These approaches, which take come to be known as systems biology, have not coalesced into a single defined entity, simply rather cover a broad class of methods that all seek to arrive at a deeper and global agreement of biological processes and the complex inter-relationships of systems that compose an organism [97–100].
The general idea guiding the study of systems biology is that to understand the full procedure by which specified biologic systems role, one needs both empirical data and structured models of existing cognition. In the electric current era, the availability of technology to excerpt data measuring a wide variety of both inputs and outputs of molecular systems is greater than e'er. Thus, it is relatively elementary to obtain simultaneous detailed information near genomic, transcriptomic, proteomic and other measures. There is also an ever-increasing knowledge base of operations consisting of models of genetic and protein networks, equally well as other models of immune part. The central to constructive systems biology research is to effectively utilize robust multivariate statistical analyses of these data in the context of the existing biological knowledge base. These analyses brand information technology possible to either modify known models or to confirm and refine already-described models. Such approaches conduct the promise of making information technology possible to more than deeply understand the initiation and maintenance of immune responses [2,96,100].
The current research grouping has initiated a series of studies inside the context of a systems biology arroyo in lodge to more deeply understand the mechanistic underpinnings and complexities of diminished vaccine response in older adults. The authors organize information from a wide variety of sources, including genetic polymorphisms, cistron transcripts, epigenetics, genetic pathways and protein–protein interactions. Using these data sources every bit inputs, the authors employ a variety of state-of-the-art statistical models and approaches to determine the extent to which the interplay of these information clarify existing models or bring new understandings that may lead to the development of novel biological models.
Specifically, a systems biology generated immune profile will be constructed effectually time points associated with distinct temporal stages of influenza vaccine response. The baseline data, or solar day 0, correspond with prevaccination amnesty. Days iii, 28 and 75 will be associated with innate, adaptive and the immune arrangement's return to homeostastis, respectively. The authors will and then accept a singled-out set of data points for each individual over a broad duration of immune response to seasonal flu vaccination. The innovation of this study lies in pairing traditional influenza vaccination outcomes, such equally cellular and humoral measures, with flow cytometric markers for adaptive and innate immunity, proteomics and cutting-border technologies such as side by side-generation mRNA sequencing (Figure 1). The authors also incorporate assays to quantify and compare the contribution of immunosenescence markers to vaccine response by measuring TCR diversity, CD28 expression and TCR excision circles assay.
Systems biology approach to developing an influenza A/H1N1 vaccine-induced immune profile
Multifunction immune and systems analysis over the duration of vaccine response will be used to determine individual immune outcomes, functional pathways and longitudinal immune profiles that will pb to the caption and prediction of immune response to influenza A/H1N1 vaccine. This will be accomplished using a fusion of traditional measures of humoral, cellular and innate immunity, paired with measures of factor regulation and large-scale analysis of protein response. Allowed response to seasonal influenza vaccination will be measured after in vitro stimulation of subject field peripheral blood mononuclear cells with live influenza A/California/H1N1 virus. Assays specific to markers of immunosenescence volition also be used to measure the influence of age on immune response to vaccine.
Once all data have been generated and analyzed in the context of the current biological knowledge base, the authors will utilize the findings to examine the unabridged spectrum of biological responses and compare and contrast them across a range of ages and immunization strategies. This will enable the authors to comprehensively empathise interactions among the components of the aging allowed system and their touch on the development and maintenance of immunity to flu vaccine. Ultimately, this volition pb to a method of more directed development of vaccines confronting influenza, peradventure by 'opposite engineering' effectually identified genetic or cellular elements.
Like approaches have already been practical and these have led to novel information relative to processes by which immunogenicity might be induced. The earliest case of this is the case of xanthous fever vaccine, where a large collection of data gathered beyond multiple time points were analyzed with multivariate statistical techniques to identify a collection of factor signatures that predicted the immunogenicity of the YF-17D vaccine [96]. Importantly, these cistron signatures were validated in an independent sample prepare; an important footstep in the research procedure when circuitous statistical approaches are applied with the goal of integrating information across a number of high-throughput technologies and existing cognition bases. The advantage offered by this approach to studying immune responses is in its focus on simultaneously studying a large number of input and output information; something that more closely approximates the reality of the complex interactions that take place inside living organisms mounting an immune response against an antigen. Classical approaches that are typically used to written report correlates of immunity tend to focus on simple associations between a unmarried input and a single output, peradventure while adjusting for a small number of potentially contributing factors, and are therefore not able to provide insight into the total cellular and immunologic milieu. Because of this, it is essential that research exist extended into the realm of systems biology, where information across a wide range of data sources can be integrated to provide insight into the immunologic processes.
Moving forrad
This review has briefly outlined the epidemiology of influenza in older persons, acknowledging the loftier rates of morbidity and mortality that older adults experience as a issue of influenza infection. In addition, the huge economical costs associated with influenza resulting in increased medical care, lost work and lost time in school, in tandem with annual epidemics of influenza (and periodic pandemics), combine to make prevention of flu a major public health business organisation. An additional and pertinent temporal trend must also be recognized, and that is the rapid increase in the aging of populations throughout the world. For example, in the USA, the fastest growing segment of the population is individuals over the age of 85 years. The implications are considerable. Older persons are increasing in number, have increased rates of disease, hospitalization, medical care use and death from increasing virulent strains of flu, in the context of yearly epidemics, and respond poorly to current influenza vaccines. It therefore becomes imperative that the research calendar exist expanded to both empathise the mechanisms that result in poor immunity in older persons, and use such information to devise more than immunogenic influenza vaccine candidates.
Disquisitional to our work, and to progress in the field, is to 'unravel' the complexity of the immune response in older persons, and to understand how it differs from younger persons. The chore is daunting, although fabricated easier by the plethora of loftier-throughput, high-dimensional technologies speedily becoming available at an affordable price. A more serious obstruction, nonetheless, are the bioinformatics personnel and processes needed to analyze and brand sense of such data. Consider that the combination of transcriptomic, other immunophenotyping and sequencing data tin can effect in a terabyte of information in just one experiment involving a single subject field. Analyzing such data in the context of models built on the current understanding of the immune response network theory and a vaccinomics arroyo requires a pregnant investment in devising and testing bioinformatics models [1,89–92,101]. In many cases, the current models are only insufficient and reflect the difficulty in reducing extremely complex systems to more simple models.
Every bit the authors take reviewed, immunosenescence has far-reaching implications in terms of generating immune responses on innate, adaptive, T-jail cell and B-jail cell function. Further enquiry is needed on the critical changes and impairments that together result in immunosenescence, and possibilities for reversing agin changes associated with the aging allowed organization. Important findings have been published, and progress fabricated – but there is a long way to go to meet the challenge of protecting an crumbling population against infectious diseases for which they are particularly susceptible.
Practiced commentary
With the approving of an HD-TIV for older adults, novel vaccines are being developed to address the upshot of immunosenescence. Even so, as stated previously, both the humoral and cellular responses in Hd-TIV-vaccinated older adults exercise not accomplish the same level as those in SD-TIV-vaccinated younger adults [28]. With the emergence of highly pathogenic influenza strains and a decrease in vaccine response in older adults, nosotros have to consider a different and more directed arroyo to vaccine research and evolution. To truly understand why vaccine efficacy decreases with age, we will accept to decrease our dependence on reductionist-based science [102]. Although the allowed arrangement can exist thought of every bit the summation of multiple smaller parts (innate and adaptive), aging causes too many complex alterations to these systems to effort to sympathise the whole of immunosenscence by focusing on a single component.
Our own work, and that of others, is directed at just such issues. Importantly, the NIH has developed and funded a inquiry program that seeks to uncover drivers of immune response to viral and other vaccines. The Human Immunology Project Consortium is currently funding seven centers throughout the USA to perform exactly the systems-level research work described above [203]. In add-on, through this program funds are available to finance preliminary human-based studies that are consistent with the priorities of the consortium, and that are performed in collaboration with one of the funded primary centers.
5-twelvemonth view
Recent innovative work demonstrates that a systems biology approach can be successful in elucidating predicative markers of immune response [96]. We believe that our approach, and others like it, will be adopted to not only gain a thorough understanding of host interactions with vaccines, but will as well exist practical to the interactions betwixt host and specific pathogens.
Our model is unique in that we focus on the influence of immunosenescence on seasonal influenza vaccination, simply immunosenescence is a contributing factor in host response to other viral vaccines also. Interestingly, the elderly exhibit a delayed antibody response to yellowish fever vaccination (YF-17D) and an increment in adverse events [103]. In add-on, both cell-mediated immunity and antibody response against canker zoster vaccine declines with age [104]. If we are successful in developing a holistic predictive immune profile to seasonal influenza vaccination, this model tin be applied to inquiry focusing on other vaccine systems and the contribution of immunosenescence. Such work will be accelerated past increasing complex bioinformatc models that volition permit u.s. to understand the simultaneous contributions of genetic, proteomic, epigenetic and cellular systems; and ever-expanding, high-dimensional, high-throughput, whole systems-level assays becoming available.
Footnotes
For reprint orders, please contact moc.sweiver-trepxe@stnirper
Financial & competing interests disclosure
GA Poland is the chair of a Prophylactic Evaluation Committee for investigational vaccine trials being conducted by Merck Enquiry Laboratories. GA Poland offers consultative advice on new vaccine development to Merck & Co., Inc., Avianax, Theraclone Sciences (formally Spaltudaq Corporation), MedImmune LLC, Liquidia Technologies, Inc., Emergent BioSolutions, Novavax, Dynavax, EMD Serono, Inc., Novartis Vaccines and Therapeutics and PAXVAX, Inc. He is also the co-inventor of intellectual property licensed to TapImmune Inc. IG Ovsyannikova is a co-inventor of intellectual holding licensed to TapImmune Inc. R Jacobson is a member of a safety review committee for a postlicensure study funded by Merck & Co. apropos the safety of a man papillomavirus vaccine. He is also a member of a data monitoring committee for an investigational vaccine trial funded by Merck & Co. He besides serves as a main investigator for 2 studies, including one funded past Novartis International for its licensed meningococcal conjugate vaccine and one funded by Pfizer, Inc. for its licensed pneumococcal conjugate vaccine. The authors acknowledge support from NIH grant U01AI089859 for this piece of work. The authors have no other relevant affiliations or financial involvement with whatever organization or entity with a financial interest in or fiscal conflict with the bailiwick affair or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
References
Papers of special annotation have been highlighted equally:
• of interest
•• of considerable interest
1•. Poland GA, Kennedy RB, Ovsyannikova IG. Vaccinomics and personalized vaccinology: is science leading the states toward a new path of directed vaccine development and discovery? PLoS Pathog. 2011;7(12):e1002344. Directed approach toward vaccine development based on the science of vaccinomics and personalized medicine. [PMC complimentary article] [PubMed] [Google Scholar]
two. Oberg AL, Kennedy RB, Li P, Ovsyannikova IG, Poland GA. Systems biology approaches to new vaccine development. Curr Opin Immunol. 2011;23(iii):436–443. [PMC free article] [PubMed] [Google Scholar]
three. Hope-Simpson RE. The role of season in the epidemiology of influenza. J Hyg (Lond) 1981;86(one):35–47. [PMC free article] [PubMed] [Google Scholar]
four. Shaman J, Pitzer VE, Viboud C, Grenfell BT, Lipsitch M. Absolute humidity and the seasonal onset of flu in the continental United States. PLoS Biol. 2010;8(2):e1000316. [PMC free commodity] [PubMed] [Google Scholar]
5. Dowell SF. Seasonality – still disruptive. Epidemiol Infect. 2012;140(ane):87–90. [PubMed] [Google Scholar]
six. Cannell JJ, Vieth R, Umhau JC, et al. Epidemic influenza and vitamin D. Epidemiol Infect. 2006;134(half-dozen):1129–1140. [PMC free commodity] [PubMed] [Google Scholar]
7. Barker WH, Borisute H, Cox C. A study of the bear upon of influenza on the functional status of frail older people. Arch Intern Med. 1998;158(6):645–650. [PubMed] [Google Scholar]
8. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the U.s.a.. JAMA. 2004;292(11):1333–1340. [PubMed] [Google Scholar]
ix. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289(ii):179–186. [PubMed] [Google Scholar]
10. Nordin J, Mullooly J, Poblete Due south, et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis. 2001;184(6):665–670. [PubMed] [Google Scholar]
11. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The almanac touch on of seasonal flu in the US: measuring illness brunt and costs. Vaccine. 2007;25(27):5086–5096. [PubMed] [Google Scholar]
12. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-bullheaded placebo-controlled trial. JAMA. 1994;272(21):1661–1665. [PubMed] [Google Scholar]
thirteen•. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972;70(four):767–777. An important placebo-controlled report measuring vaccine efficacy against influenza affliction in the elderly. [PMC gratis article] [PubMed] [Google Scholar]
14. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull. 1979;35(1):69–75. [PubMed] [Google Scholar]
xv. Goodwin K, Viboud C, Simonsen 50. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006;24(8):1159–1169. [PubMed] [Google Scholar]
16•. Mysliwska J, Trzonkowski P, Szmit E, Brydak LB, Machala Thou, Mysliwski A. Immunomodulating upshot of influenza vaccination in the elderly differing in health condition. Exp Gerontol. 2004;39(10):1447–1458. This meta-analysis review suggests that antibody response to flu vaccination is diminished in older adults. [PubMed] [Google Scholar]
17. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-prison cell immunity to flu. N Engl J Med. 1983;309(1):thirteen–17. [PubMed] [Google Scholar]
18. Doherty PC, Topham DJ, Tripp RA. Establishment and persistence of virus-specific CD4+ and CD8+ T cell memory. Immunol Rev. 1996;150:23–44. [PubMed] [Google Scholar]
nineteen. Shahid Z, Kleppinger A, Gentleman B, Falsey AR, McElhaney JE. Clinical and immunologic predictors of flu illness among vaccinated older adults. Vaccine. 2010;28(38):6145–6151. [PMC gratis article] [PubMed] [Google Scholar]
twenty. McElhaney JE, Gravenstein Southward, Upshaw CM, et al. Granzyme B: a marker of adventure for influenza in institutionalized older adults. Vaccine. 2001;19(27):3744–3751. [PubMed] [Google Scholar]
21. McElhaney JE, Xie D, Hager WD, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol. 2006;176(10):6333–6339. [PubMed] [Google Scholar]
22. Lee JB, Oelke 1000, Ramachandra L, Canaday DH, Schneck JP. Decline of influenza-specific CD8+ T cell repertoire in good for you geriatric donors. Immun Ageing. 2011;8:6. [PMC free article] [PubMed] [Google Scholar]
23. Zhou X, McElhaney JE. Age-related changes in retentiveness and effector T cells responding to influenza A/H3N2 and pandemic A/H1N1 strains in humans. Vaccine. 2011;29(11):2169–2177. [PMC free article] [PubMed] [Google Scholar]
24. Deng Y, Jing Y, Campbell AE, Gravenstein S. Historic period-related impaired blazon one T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J Immunol. 2004;172(6):3437–3446. [PubMed] [Google Scholar]
25. Gross PA, Quinnan GV, Jr, Weksler ME, Gaerlan PF, Denning CR. Immunization of elderly people with loftier doses of flu vaccine. J Am Geriatr Soc. 1988;36(3):209–212. [PubMed] [Google Scholar]
26. Palache AM, Beyer WE, Sprenger MJ, et al. Antibiotic response afterwards flu immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response report in elderly nursing-domicile residents and young volunteers. Vaccine. 1993;eleven(1):3–9. [PubMed] [Google Scholar]
27. Falsey AR, Treanor JJ, Tornieporth North, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009;200(2):172–180. [PubMed] [Google Scholar]
28. Chen WH, Cantankerous AS, Edelman R, Sztein MB, Blackwelder WC, Pasetti MF. Antibiotic and Th1-type prison cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose flu vaccine. Vaccine. 2011;29(xvi):2865–2873. [PMC free article] [PubMed] [Google Scholar]
29. Targonski PV, Jacobson RM, Poland GA. Immunosenescence: function and measurement in flu vaccine response among the elderly. Vaccine. 2007;25(sixteen):3066–3069. [PubMed] [Google Scholar]
xxx•. Janeway CA, Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197–216. Although immunization with loftier-dose influenza vaccine increases both antibody and cell-mediated responses, they never reach the same level of responses as those in young adults vaccinated with standard-dose flu vaccine. [PubMed] [Google Scholar]
31. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of unmarried-stranded RNA. Scientific discipline. 2004;303(5663):1529–1531. [PubMed] [Google Scholar]
32. Aldridge JR, Jr, Moseley CE, Boltz DA, et al. TNF/iNOS-producing dendritic cells are the necessary evil of lethal flu virus infection. Proc Natl Acad Sci Us. 2009;106(13):5306–5311. [PMC free commodity] [PubMed] [Google Scholar]
33. Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J Exp Med. 2009;206(one):79–87. [PMC costless article] [PubMed] [Google Scholar]
34. Koyama S, Ishii KJ, Kumar H, et al. Differential role of TLR- and RLR-signaling in the allowed responses to influenza A virus infection and vaccination. J Immunol. 2007;179(seven):4711–4720. [PubMed] [Google Scholar]
35. Julkunen I, Melén One thousand, Nyqvist M, Pirhonen J, Sareneva T, Matikainen S. Inflammatory responses in influenza A virus infection. Vaccine. 2000;19(Suppl 1):S32–S37. [PubMed] [Google Scholar]
36. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1(2):135–145. [PubMed] [Google Scholar]
37. Kawai T, Akira S. The part of blueprint-recognition receptors in innate amnesty: update on Toll-like receptors. Nat Immunol. 2010;11(5):373–384. [PubMed] [Google Scholar]
38. van Duin D, Mohanty Southward, Thomas V, et al. Age-associated defect in man TLR-1/ii function. J Immunol. 2007;178(ii):970–975. [PubMed] [Google Scholar]
39. Kong KF, Delroux K, Wang X, et al. Dysregulation of TLR3 impairs the innate immune response to West Nile virus in the elderly. J Virol. 2008;82(15):7613–7623. [PMC costless article] [PubMed] [Google Scholar]
40. Sridharan A, Esposo G, Kaushal M, et al. Age-associated dumb plasmacytoid dendritic cell functions lead to decreased CD4 and CD8 T jail cell immunity. Age (Dordr) 2011;33(3):363–376. [PMC free commodity] [PubMed] [Google Scholar]
41. Panda A, Qian F, Mohanty S, et al. Age-associated decrease in TLR function in principal homo dendritic cells predicts flu vaccine response. J Immunol. 2010;184(5):2518–2527. [PMC free article] [PubMed] [Google Scholar]
42. Reiser H, Stadecker MJ. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med. 1996;335(eighteen):1369–1377. [PubMed] [Google Scholar]
43••. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2(ii):116–126. Demonstrates a direct clan betwixt a diminished Toll-similar receptor function in anile dendritic cells and antibody response to influenza vaccine. [PubMed] [Google Scholar]
44. van Duin D, Allore HG, Mohanty Southward, et al. Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adults. J Infect Dis. 2007;195(11):1590–1597. [PubMed] [Google Scholar]
45. Lodoen MB, Lanier LL. Natural killer cells every bit an initial defence against pathogens. Curr Opin Immunol. 2006;18(four):391–398. [PMC gratis article] [PubMed] [Google Scholar]
46. Achdout H, Arnon TI, Markel G, et al. Enhanced recognition of human NK receptors after influenza virus infection. J Immunol. 2003;171(two):915–923. [PubMed] [Google Scholar]
47. Denney Fifty, Aitken C, Li CK, et al. Reduction of natural killer but not effector CD8 T lymphocytes in three sequent cases of severe/lethal H1N1/09 influenza A virus infection. PLoS Ane. 2010;5(5):e10675. [PMC free commodity] [PubMed] [Google Scholar]
48. Ennis FA, Meager A, Beare Every bit, et al. Interferon induction and increased natural killer-cell activity in influenza infections in human. Lancet. 1981;two(8252):891–893. [PubMed] [Google Scholar]
49. Gazit R, Gruda R, Elboim M, et al. Lethal flu infection in the absence of the natural killer cell receptor gene Ncr1. Nat Immunol. 2006;seven(5):517–523. [PubMed] [Google Scholar]
50. Schapiro JM, Segev Y, Rannon Fifty, Alkan M, Rager-Zisman B. Natural killer (NK) cell response after vaccination of volunteers with killed influenza vaccine. J Med Virol. 1990;xxx(three):196–200. [PubMed] [Google Scholar]
51. Franceschi C, Monti D, Sansoni P, Cossarizza A. The immunology of exceptional individuals: the lesson of centenarians. Immunol Today. 1995;16(i):12–16. [PubMed] [Google Scholar]
52. Zhang Y, Wallace DL, de Lara CM, et al. In vivo kinetics of human natural killer cells: the furnishings of ageing and acute and chronic viral infection. Immunology. 2007;121(2):258–265. [PMC costless commodity] [PubMed] [Google Scholar]
53. Franceschi C, Bonafè M, Valensin Due south, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244–254. [PubMed] [Google Scholar]
54. Giuliani N, Sansoni P, Girasole Thou, et al. Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 showroom different patterns of age- and menopause-related changes. Exp Gerontol. 2001;36(3):547–557. [PubMed] [Google Scholar]
55. Ferrucci L, Harris TB, Guralnik JM, et al. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc. 1999;47(half-dozen):639–646. [PubMed] [Google Scholar]
56. Leng SX, Xue QL, Tian J, Walston JD, Fried LP. Inflammation and frailty in older women. J Am Geriatr Soc. 2007;55(half-dozen):864–871. [PubMed] [Google Scholar]
57. Stout-Delgado HW, Du West, Shirali Air conditioning, Booth CJ, Goldstein DR. Aging promotes neutrophil-induced bloodshed by augmenting IL-17 production during viral infection. Jail cell Host Microbe. 2009;6(5):446–456. [PMC gratis commodity] [PubMed] [Google Scholar]
58. Germain RN. T-cell development and the CD4-CD8 lineage decision. Nat Rev Immunol. 2002;ii:309–322. [PubMed] [Google Scholar]
59. Taub DD, Longo DL. Insights into thymic aging and regeneration. Immunol Rev. 2005;205:72–93. [PubMed] [Google Scholar]
sixty. Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration afterward intensive chemotherapy. Northward Engl J Med. 1995;332(three):143–149. [PubMed] [Google Scholar]
61. Mackall CL, Gress RE. Thymic crumbling and T-jail cell regeneration. Immunol Rev. 1997;160:91–102. [PubMed] [Google Scholar]
62. Ahmed M, Lanzer KG, Yager EJ, Adams PS, Johnson LL, Blackman MA. Clonal expansions and loss of receptor diversity in the naive CD8 T cell repertoire of aged mice. J Immunol. 2009;182(2):784–792. [PMC gratis article] [PubMed] [Google Scholar]
63. Yager EJ, Ahmed M, Lanzer Yard, Randall TD, Woodland DL, Blackman MA. Age-associated turn down in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J Exp Med. 2008;205(3):711–723. [PMC complimentary article] [PubMed] [Google Scholar]
64. Saule P, Trauet J, Dutriez 5, Lekeux V, Dessaint JP, Labalette M. Accumulation of retentivity T cells from childhood to erstwhile age: cardinal and effector retention cells in CD4(+) versus effector retentiveness and terminally differentiated retention cells in CD8(+) compartment. Mech Ageing Dev. 2006;127(3):274–281. [PubMed] [Google Scholar]
65. Schwanninger A, Weinberger B, Weiskopf D, et al. Age-related appearance of a CMV-specific loftier-avidity CD8+ T cell clonotype which does not occur in young adults. Immun Ageing. 2008;five:14. [PMC free article] [PubMed] [Google Scholar]
66. Almanzar G, Schwaiger S, Jenewein B, et al. IFN-γ production past CMV-specific CD8+ T cells is high in elderly donors. Exp Gerontol. 2004;39(5):863–five. author reply 867. [PubMed] [Google Scholar]
67. Effros RB, Boucher N, Porter V, et al. Pass up in CD28+ T cells in centenarians and in long-term T prison cell cultures: a possible cause for both in vivo and in vitro immunosenescence. Exp Gerontol. 1994;29(6):601–609. [PubMed] [Google Scholar]
68. Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O'Fallon WM, Weyand CM. Value of immunological markers in predicting responsiveness to flu vaccination in elderly individuals. J Virol. 2001;75(24):12182–12187. [PMC gratuitous article] [PubMed] [Google Scholar]
69. Wagar LE, Rosella Fifty, Crowcroft Due north, et al. Humoral and cell-mediated immunity to pandemic H1N1 influenza in a Canadian cohort one yr post-pandemic: implications for vaccination. PLoS 1. 2011;half dozen(11):e28063. [PMC free commodity] [PubMed] [Google Scholar]
seventy•. Haynes L, Eaton SM. The outcome of historic period on the cognate part of CD4+ T cells. Immunol Rev. 2005;205:220–228. The frequencies of CD8+ CD28− T cells can exist used to predict influenza vaccine response in elderly people. [PMC free article] [PubMed] [Google Scholar]
71. Allman D, Miller JP. B cell development and receptor diversity during aging. Curr Opin Immunol. 2005;17(5):463–467. [PubMed] [Google Scholar]
72. Frasca D, Riley RL, Blomberg BB. Humoral immune response and B-cell functions including immunoglobulin course switch are downregulated in anile mice and humans. Semin Immunol. 2005;17(5):378–384. [PubMed] [Google Scholar]
73. Gelder CM, Lambkin R, Hart KW, et al. Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine. J Infect Dis. 2002;185(1):114–117. [PubMed] [Google Scholar]
74. Lambkin R, Novelli P, Oxford J, Gelder C. Human genetics and responses to influenza vaccination: clinical implications. Am J Pharmacogenomics. 2004;4(v):293–298. [PubMed] [Google Scholar]
75. Marchant A, Pihlgren M, Goetghebuer T, et al. Medical Enquiry Council Gambia Twin Study Group. Predominant influence of environmental determinants on the persistence and avidity maturation of antibody responses to vaccines in infants. J Infect Dis. 2006;193(xi):1598–1605. [PubMed] [Google Scholar]
76. Poland GA, Ovsyannikova IG, Jacobson RM. Immunogenetics of seasonal influenza vaccine response. Vaccine. 2008;26(Suppl 4):D35–D40. [PMC costless article] [PubMed] [Google Scholar]
77. Albright FS, Orlando P, Pavia AT, Jackson GG, Cannon Albright LA. Bear witness for a heritable predisposition to death due to influenza. J Infect Dis. 2008;197(i):xviii–24. [PubMed] [Google Scholar]
78•. Diaz-Mitoma F, Alvarez-Maya I, Dabrowski A, et al. Transcriptional analysis of human peripheral blood mononuclear cells after influenza immunization. J Clin Virol. 2004;31(ii):100–112. This review addresses the immunogentic influences on the humoral response to flu vaccine. [PubMed] [Google Scholar]
fourscore. Hashiba T, Suzuki M, Nagashima Y, et al. Adenovirus-mediated transfer of heme oxygenase-ane cDNA attenuates severe lung injury induced past the flu virus in mice. Gene Ther. 2001;viii(19):1499–1507. [PubMed] [Google Scholar]
81. Kash JC, Basler CF, Garcia-Sastre A, et al. Global host immune response: pathogenesis and transcriptional profiling of blazon A flu viruses expressing the hemagglutinin and neuraminidase genes from the 1918 pandemic virus. J Virol. 2004;78:9499–9511. [PMC free article] [PubMed] [Google Scholar]
82. Cummins NW, Weaver EA, May SM, et al. Heme oxygenase-ane regulates the immune response to flu virus infection and vaccination in anile mice. FASEB J. 2012;26(7):2911–2918. [PMC free article] [PubMed] [Google Scholar]
83. Gelder C, Davenport M, Barnardo M, et al. 6 unrelated HLA-DR-matched adults recognize identical CD4+ T jail cell epitopes from influenza A haemagglutinin that are not but peptides with loftier HLA-DR binding affinities. Int Immunol. 1998;10(2):211–222. [PubMed] [Google Scholar]
84. Gelder CM, Lamb JR, Askonas BA. Human CD4+ T-jail cell recognition of influenza A virus hemagglutinin subsequently subunit vaccination. J Virol. 1996;70(7):4787–4790. [PMC costless article] [PubMed] [Google Scholar]
85. Benefaction AC, de Mutsert G, Graus YM, et al. Sequence variation in a newly identified HLA-B35-restricted epitope in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. J Virol. 2002;76(v):2567–2572. [PMC gratis article] [PubMed] [Google Scholar]
86. Haynes LM, Moore DD, Kurt-Jones EA, Finberg RW, Anderson LJ, Tripp RA. Involvement of toll-like receptor four in innate immunity to respiratory syncytial virus. J Virol. 2001;75(22):10730–10737. [PMC costless article] [PubMed] [Google Scholar]
87. Puthothu B, Forster J, Heinzmann A, Krueger K. TLR-4 and CD14 polymorphisms in respiratory syncytial virus associated affliction. Dis Markers. 2006;22(5–6):303–308. [PMC free article] [PubMed] [Google Scholar]
88. Mibayashi Grand, Martínez-Sobrido L, Loo YM, Cárdenas WB, Gale Yard, Jr, García-Sastre A. Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J Virol. 2007;81(two):514–524. [PMC complimentary article] [PubMed] [Google Scholar]
89. Poland GA, Levine MM, Clemens JD. Developing the next generation of vaccinologists. Vaccine. 2010;28(52):8227–8228. [PubMed] [Google Scholar]
90. Ovsyannikova IG, Poland GA. Vaccinomics: current findings, challenges and novel approaches for vaccine evolution. AAPS J. 2011;13(3):438–444. [PMC complimentary article] [PubMed] [Google Scholar]
91. Poland GA, Ovsyannikova IG, Kennedy RB, Haralambieva IH, Jacobson RM. Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections. OMICS. 2011;15(9):625–636. [PMC free article] [PubMed] [Google Scholar]
92. Poland GA, Ovsyannikova IG, Jacobson RM. The Jordan Study: Accelerated Evolution of Vaccines. NIH; MD, United states of america: 2012. Vaccinomics and personalized vaccinology. In; pp. 11–18. [Google Scholar]
93. Tegnér J, Nilsson R, Bajic VB, Björkegren J, Ravasi T. Systems biology of innate immunity. Cell Immunol. 2006;244(2):105–109. [PMC gratis article] [PubMed] [Google Scholar]
94. Draghici S, Khatri P, Tarca AL, et al. A systems biology arroyo for pathway level analysis. Genome Res. 2007;17(ten):1537–1545. [PMC gratuitous commodity] [PubMed] [Google Scholar]
95. Herrgård MJ, Swainston Northward, Dobson P, et al. A consensus yeast metabolic network reconstruction obtained from a customs approach to systems biology. Nat Biotechnol. 2008;26(10):1155–1160. [PMC free article] [PubMed] [Google Scholar]
96. Querec TD, Akondy RS, Lee EK, et al. Systems biological science arroyo predicts immunogenicity of the yellowish fever vaccine in humans. Nat Immunol. 2009;x(one):116–125. [PMC free article] [PubMed] [Google Scholar]
97. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based arroyo to homo affliction. Nat Rev Genet. 2011;12(1):56–68. [PMC gratuitous article] [PubMed] [Google Scholar]
98••. Kohl P, Crampin EJ, Quinn TA, Noble D. Systems biological science: an approach. Clin Pharmacol Ther. 2010;88(1):25–33. A systems biological science approach can be used to elucidate predictive markers of vaccine-induced immunogenicity. [PubMed] [Google Scholar]
99. Midgley CM, Putz MM, Weber JN, Smith GL. Vaccinia virus strain NYVAC induces substantially lower and qualitatively unlike man antibody responses compared with strains Lister and Dryvax. J Gen Virol. 2008;89(Pt 12):2992–2997. [PMC free article] [PubMed] [Google Scholar]
101. Haralambieva IH, Poland GA. Vaccinomics, predictive vaccinology and the future of vaccine development. Future Microbiol. 2010;five(12):1757–1760. [PubMed] [Google Scholar]
102. Poland GA, Marcuse EK. Developing vaccine policy: attributes of 'just policy' and a proposed template to guide decision and policy making. Vaccine. 2011;29(44):7577–7578. [PubMed] [Google Scholar]
103. Roukens AH, Soonawala D, Joosten SA, et al. Elderly subjects have a delayed antibody response and prolonged viraemia following yellowish fever vaccination: a prospective controlled cohort written report. PLoS One. 2011;6(12):e27753. [PMC gratuitous commodity] [PubMed] [Google Scholar]
104. Levin MJ. Varicella vaccination of immunocompromised children. J Infect Dis. 2008;197(Suppl 2):S200–S206. [PubMed] [Google Scholar]
Websites
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514506/
0 Response to "How Flu Vaccine Provide Immuinty Agains Flue"
Post a Comment